> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-038.md). # BRE 038 ## TTFields, Temozolomide, and Clinical Safety in Glioblastoma **Clinical Cancer Name:** Glioblastoma\ **Common Cancer Name:** Aggressive Brain Cancer ## Source Chen, Y., Chen, Y., Zhen, H., & Lou, D. (2025). *Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials.* *Egyptian Journal of Neurosurgery, 40, 20.* *** ## BRS Score **BRS:** 8.9 / 10\ **STEMD:** S10 / T10 / E9 / M6 / D9\ **External Evidence Level:** High meta-analysis clinical safety evidence ## Score Interpretation BRE-038 receives a strong score because it synthesizes randomized clinical trial safety data across 994 glioblastoma patients. Its mechanism score is lower because this study does not directly test biological mechanisms such as ROS, mitochondria, calcium signaling, autophagy, or DNA repair. Its strongest contribution is clinical safety and translational scalability. *** ## Entry Summary BRE-038 asks a clinical safety question: When TTFields are added to temozolomide for glioblastoma, does the combination create more systemic toxicity? This meta-analysis compared TTFields plus temozolomide against temozolomide alone in randomized trials. In simple language: A treatment may help patients live longer, but it must also be tolerable. BRE-038 helps answer whether adding TTFields creates major extra side effects throughout the body. *** ## What BREXAtlas Found BREXAtlas identifies this primary clinical chain: TTFields\ +\ Temozolomide\ ↓\ Improved survival benefit\ ↓\ Minimal systemic toxicity increase\ ↓\ Clinical deployment feasibility The key finding is that TTFields combined with temozolomide demonstrated a favorable safety profile without major increases in systemic adverse events across randomized trials. *** ## Questions This BRE Helps Answer
What is temozolomide? Temozolomide is a chemotherapy drug commonly used in glioblastoma treatment. What BREXAtlas found:\ BRE-038 evaluates TTFields when combined with temozolomide, comparing the combination against temozolomide alone.
Did TTFields significantly increase systemic toxicity? What BREXAtlas found:\ No major increase in systemic toxicity was identified. The extraction reports similar rates of hematologic, neurologic, gastrointestinal, respiratory, and psychiatric adverse events.
Why is safety important for TTFields? TTFields are used over long periods and require patient adherence. What BREXAtlas found:\ BRE-038 supports clinical tolerability, long-term compliance feasibility, safety validation, and standard-of-care integration.
Does this entry prove a new TTFields mechanism? What BREXAtlas found:\ No. BRE-038 strengthens clinical translation ontology. It does not directly evaluate mitochondrial respiration, ROS generation, autophagy, calcium signaling, membrane depolarization, DNA repair pathways, or bioelectric network disruption.
*** ## Study Classification | Category | Classification | | --------------------------------------- | ------------------------------------------------------- | | Study Type | Meta-analysis of randomized clinical trials | | Tissue Category | Glioblastoma; CNS oncology | | Patient Population | 994 patients | | TTFields + Temozolomide | 572 patients | | Temozolomide Alone | 422 patients | | Exposure System | TTFields + temozolomide clinical glioblastoma protocols | | Primary Focus | Adverse outcomes / safety | | Direct Mechanism Evidence | No | | Clinical Translation Evidence | Yes | | Suitable for Safety Index | Yes | | Suitable for Clinical Translation Index | Yes | | Suitable for Glioblastoma Index | Yes | *** ## Clinical Variables BRE-038 identified adverse-event categories including: * Blood disorders * Gastrointestinal disorders * CNS disorders * Psychiatric disorders * Respiratory disorders * Metabolic disorders These variables matter because they define the clinical safety comparison between combination therapy and temozolomide alone. *** ## Mechanisms / Clinical Concepts **MEC-050: TTFields Chemotherapy Co-Amplification** TTFields may support clinical benefit when combined with standard-of-care chemotherapy. **MEC-051: Clinical Tolerability Preservation** TTFields may provide therapeutic amplification without proportional increases in systemic toxicity. **MEC-048: TTFields-Induced Immune Recruitment** BRE-038 strengthens clinical deployment confidence but does not directly test immune recruitment. **PRN-032: Therapeutic Benefit–Toxicity Separation** TTFields may demonstrate clinical benefit while maintaining relatively low systemic toxicity compared with many systemic cancer therapies. *** ## Discoveries **DISC-021: Clinical Systems-Level TTFields Integration** BRE-038 strengthens the idea that TTFields can be integrated into clinical glioblastoma treatment systems. **DISC-023: Clinical Safety-Convergence Architecture** BREXAtlas identifies this as a clinical discovery relationship: TTFields studies suggest therapeutic efficacy may be achievable without the toxicity burden typically associated with many systemic cancer therapies. *** ## Connections to Other BRE Entries ### Connected to BRE-036 BRE-036 established clinical TTFields translation in glioblastoma, including 200 kHz optimization, >18 h/day compliance, temozolomide combination, and systems-level mechanisms. BRE-038 strengthens the safety side of that clinical translation pathway. ### Connected to BRE-017 BRE-017 showed combination amplification through mitotic checkpoint vulnerability. BRE-038 does not test checkpoint biology, but it supports the broader clinical question of whether TTFields can be combined with other therapies safely. ### Connected to BRE-018 BRE-018 showed TTFields could create radiation vulnerability through DNA repair suppression in lung cancer models. BRE-038 does not test DNA repair, but it strengthens the clinical combination framework by showing tolerability in glioblastoma protocols. ### Connected to BRE-020 BRE-020 synthesized TTFields combination potential with radiotherapy and chemotherapy. BRE-038 provides clinical safety support for TTFields plus chemotherapy. ### Connected to BRE-037 BRE-037 expanded clinical TTFields translation into mesothelioma. BRE-038 supports the broader applied TTFields theme: clinical scaling requires both efficacy and tolerability. *** ## Research Gaps Identified **RG-188: Long-Term Neurocognitive Outcomes Gap** More work is needed to track long-term neurocognitive outcomes under extended TTFields use. **RG-189: Very-Long-Term Safety Monitoring Gap** Longer follow-up is needed to evaluate rare or delayed adverse effects. **RG-190: Compliance Optimization Systems Gap** Future research should improve adherence systems because TTFields therapy depends on long daily use. **RG-191: Cost-Effectiveness Modeling Gap** More health-economic modeling is needed to determine affordability and system-level value. **RG-192: Quality-of-Life Integration Gap** Future studies should evaluate quality of life alongside adverse-event rates and survival outcomes. *** ## Scientific Caution BRE-038 is a safety-focused meta-analysis. It strengthens clinical translation ontology but does not create new mitochondrial, metabolic, calcium, ROS, autophagy, or DNA-repair ontology. *** ## Why This Entry Matters For researchers, BRE-038 is important because clinical translation requires safety evidence, not only mechanism evidence. For patients and families, the simple idea is this: Adding TTFields to temozolomide did not appear to cause major extra body-wide side effects in the randomized trial data analyzed here. This does not remove the need for medical supervision or individual risk assessment. It does support the idea that TTFields can be clinically tolerable when added to standard glioblastoma therapy. *** ## Entry Conclusion BRE-038 strengthens the clinical safety branch of the BREXAtlas Encyclopedia. BRE-036 established glioblastoma TTFields clinical translation. BRE-037 showed TTFields expansion into mesothelioma. BRE-038 adds meta-analysis safety support by showing that TTFields plus temozolomide did not significantly increase systemic adverse events compared with temozolomide alone. The central question emerging from this entry is: Can TTFields provide clinical treatment benefit without adding major systemic toxicity to standard glioblastoma therapy? For BREXAtlas, BRE-038 is essential because it separates clinical safety evidence from biological mechanism evidence and supports responsible translation. --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://www.brexatlas.org/bre-001/bre-038.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.